Low-dose pioglitazone for fatty liver disease in people with type 2 diabetes
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This Phase 2 study tests whether low-dose pioglitazone can improve NASH, a type of fatty liver disease, in adults who also have type 2 diabetes. You may be able to join if your diabetes medicines and lab tests meet specific safety and stability requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and sign consent on your own (or have legal consent, if applicable).
- You’re age 21 to 75.
- You have type 2 diabetes, with recent labs or medication history showing it is controlled enough (HbA1c ≤ 9.5%).
- Your diabetes medicines must be stable for a set time (and you generally can’t start pioglitazone during the study).
- Your blood and liver/kidney tests must be within safe limits (including enough hemoglobin, platelets, albumin, and acceptable liver enzyme levels).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the liver uses energy (mitochondria) in people with type 2 diabetes and fatty liver disease. By understanding this, researchers may find better ways to treat liver problems.
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
This trial tests whether pioglitazone (a diabetes medicine) helps people who have type 2 diabetes and a specific type of heart failure where the heart pumps normally. It may improve heart failure symptoms and function in carefully selected patients.
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
Hear when a new NASH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.